FDA Approval Is "First Action" For 32% Of NMEs; Rate Less Than Other NDAs
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approved approximately one-third of new molecular entities with user fee deadlines in 2002 on the first cycle.
You may also be interested in...
Average Approval Time Is Slower For Drugs, Faster For Biologics
Average time to approval rose in 2004 to 18.7 months for NMEs, but biologics average was significantly lower at 20.2 months. 2003 averages were 17.1 for drugs, 36.9 for biologics
Average Approval Time Is Slower For Drugs, Faster For Biologics
Average time to approval rose in 2004 to 18.7 months for NMEs, but biologics average was significantly lower at 20.2 months. 2003 averages were 17.1 for drugs, 36.9 for biologics
FDA First-Cycle Approval Rate For NMEs Leaps To 50% In 2003
FDA’s efforts to increase first-cycle approvals appear to be paying off, with the agency showing a significant improvement in 2003 compared to 2002.